Omeros Corp (NASDAQ:OMER)

Thursday’s trading has closed, but OMER is being traded in the after-hours session. After-Hours quote »
26.35
Delayed Data
As of 3:59pm ET
 +0.15 / +0.57%
Today’s Change
9.76
Today|||52-Week Range
27.64
+6.34%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$974.0M

Company Description

Omeros Corp. is a clinical stage biopharmaceutical company, which engages in the discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. Its products are derived from its proprietary PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. The company also has a deep and diverse pipeline of preclinical programs as well as a platform capable of unlocking new drug targets. Omeros was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Contact Information

Omeros Corp.
201 Elliott Avenue West
Seattle Washington 98119
P:(206) 676-5000
Investor Relations:

Employees

Shareholders

Individual stakeholders8.50%
Other institutional28.48%
Mutual fund holders17.62%

Top Executives

Gregory A. DemopulosChairman, President & Chief Executive Officer
David R. TollSenior Director-Finance
Michael A. JacobsenChief Financial Officer, Treasurer, CAO & VP
George A. GaitanarisChief Scientific Officer & Vice President
J. Steven WhitakerChief Medical Officer & VP-Clinical Development

To view my watchlist

Not a member yet?

Sign up now for a free account